Results 21 to 30 of about 201 (100)

Anti-CMV therapy, what next? A systematic review

Frontiers in Microbiology, 2023
Human cytomegalovirus (HCMV) is one of the main causes of serious complications in immunocompromised patients and after congenital infection. There are currently drugs available to treat HCMV infection, targeting viral polymerase, whose use is ...
Claire Gourin, Sophie Alain, Sophie Alain, Sébastien Hantz, Sébastien Hantz   +4 more
doaj   +1 more source

Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review

JHLT Open
Background: Cytomegalovirus (CMV) remains a major cause of infection following solid organ transplant and valganciclovir prophylaxis is the standard of care. However, valganciclovir-associated myelosuppression limits its tolerability and can require dose
Alyssa K. Mezochow, MD, MSc, Kevin D. He, MD, Kathryn Whitaker, MD, Emily Blumberg, MD, Maria M. Crespo, MD, Andrew Courtwright, MD, PhD   +5 more
doaj   +1 more source

Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes

Annals of Hematology
Graft versus host disease (GVHD) is a serious side effect of allogenic stem cell transplantation (allo-SCT). Anti-thymocyte globulin (ATG) reduces GVHD but raises the risk of infections following allo-SCT.
Shuto Negishi, Kotaro Miyao, Fumiya Ohara, Kenta Motegi, Hiroya Wakabayashi, Hitomi Sawa, Yuichiro Inagaki, Masashi Sawa   +7 more
doaj   +1 more source

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

Therapeutic Advances in Hematology, 2021
Background: Letermovir prophylaxis is currently the standard of care for the prevention of cytomegalovirus (CMV) infections in allogeneic hematopoietic stem-cell transplantation (allo-HSCT).
Po-Hsien Li, Cheng-Hsien Lin, Yu-Hui Lin, Tsung-Chih Chen, Chiann-Yi Hsu, Chieh-Lin Jerry Teng   +5 more
doaj   +1 more source

Letermovir for cytomegalovirus prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation: a single-center experience

Blood Research
Purpose Letermovir prophylaxis results in a significantly lower risk of clinically significant cytomegalovirus (CMV) infection in adult hematopoietic stem cell transplant recipients.
Pai-Lin Tsai, Meng-Yao Lu, Hsiu-Hao Chang, Yung-Li Yang, Chia-Jui Du, Chang-Hsueh Wu, Shiann-Tarng Jou, Shu-Wei Chou   +7 more
doaj   +1 more source

Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis

Experimental Hematology & Oncology
Letermovir is an antiviral agent that significantly decreases the frequency of cytomegalovirus (CMV) infections following allogeneic hematopoietic stem cell transplantation (allo-HCT); however, its impact on Epstein-Barr virus (EBV) infection remains ...
Jingtao Huang, Jing Zhou, Shixuan Zhang, Ruoxuan Zhang, Zengkai Pan, Luxiang Wang, Chuanhe Jiang, Jiayu Huang, Zilu Zhang, Yanmin Zhao, Yang Cao, Xiaoxia Hu   +11 more
doaj   +1 more source

Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study

Frontiers in Cellular and Infection Microbiology
ObjectivesTo compare the efficacy and safety of letermovir and ganciclovir for cytomegalovirus (CMV) prophylaxis in adolescent patients (aged 14-17 years) undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT).MethodsThis observational ...
Ziwei Xu, Xuan Lu, Huafang Wang
doaj   +1 more source

Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide

Frontiers in Oncology, 2021
The prevention of chronic graft-versus-host disease (cGVHD) is important for recipients of hematopoietic stem-cell transplantation (HSCT). As one of the etiologies, the relationship between early T-cell recovery and subsequent cGVHD development has been ...
Toshiki Terao, Ken-ichi Matsuoka, Kentaro Narita, Takafumi Tsushima, Satoshi Yuyama, Ayumi Kuzume, Rikako Tabata, Daisuke Miura, Masami Takeuchi, Kosei Matsue   +9 more
doaj   +1 more source

Refining letermovir prophylaxis strategies and CD4 + T cell-guided discontinuation in aplastic anemia patients post-allogeneic HSCT: a retrospective analysis

European Journal of Medical Research
Introduction Cytomegalovirus (CMV) infection is a significant complication in aplastic anemia (AA) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Yuling Zhang, Xiaoqing He, Ming Zhou, Yuping Zhang, Wenjian Mo, Ruiqing Zhou, Yumiao Li, Qi Xiang, Fangfang Yang, Shilin Xu, Caixia Wang, Wei Zhou, Tingfen Deng, Shiyi Pan, LiangLiang Wu, Shunqing Wang, Xiaowei Chen   +16 more
doaj   +1 more source

Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation

Microbiology Spectrum, 2023
The use of valganciclovir as secondary prophylaxis for cytomegalovirus (CMV) infection in solid organ transplantation (SOT) is the most prevalent therapeutic choice, but it has been dismissed by the presence of resistance and toxicity.
Ana-Belén Pérez, Marta Santos Bravo, Elisa Vidal-Verdú, Aurora Páez-Vega, José-Manuel Vaquero-Barrios, José-Luis Montero, María-Ángeles Marcos, Julián Torre-Cisneros   +7 more
doaj   +1 more source